Singapore markets closed

Sofina Société Anonyme (0G2X.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
209.96+3.11 (+1.50%)
At close: 06:18PM BST
Full screen
Previous close206.86
BidN/A x N/A
AskN/A x N/A
Day's range206.20 - 211.60
52-week range170.30 - 241.60
Avg. volume5,862
Market capN/A
Beta (5Y monthly)1.06
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Reuters

    MORNING BID EUROPE-Yen traders on tenterhooks

    It's another day of nail-biting for currency traders as the will-they-won't-they debate swirls on Japan's yen-buying intervention. Friday's holiday in most of the world, barring Japan, China and some parts of U.S. markets, makes them all the more nervous. The currency's brief slide on Wednesday to a 34-year low near 152 per dollar triggered an emergency meeting of Japan's three main monetary authorities, which market participants interpreted as imminent direct intervention to stop what those authorities consider speculative currency trading.

  • Reuters SG

    India's Byju's can't access rights issue funds to pay staff

    Indian edtech startup Byju's is unable to pay staff because it can't access recently raised funds due to a legal dispute with some of its investors, founder and CEO Byju Raveendran said in an email to employees on Saturday seen by Reuters. Byju's did not immediately respond to a Reuters email seeking comment. Raveendran's email blamed four of Byju's' more than 150 investors for blocking access to funds raised through a rights issue that was completed on Feb. 28.

  • Reuters SG

    Biobest buys Brazil farm solutions provider Biotrop in $570 mln deal

    Belgian sustainable crop management provider Biobest Group has reached a deal to acquire Brazilian peer Biotrop as it looks to expand its footprint in the South American agricultural powerhouse, the companies announced on Thursday. The firms said in a joint statement Biobest has signed a binding agreement to buy an 85% stake of Biotrop, which is currently controlled by private equity firm Aqua Capital, at a valuation of 532 million euros ($569.45 million). The remaining 15% stake will be bought by Biobest after a three-year transition period, the companies said, adding they expect the deal to be completed by the end of this year.